These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37929318)

  • 1. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
    Kuter DJ; Piatek C; Röth A; Siddiqui A; Numerof RP; Dummer W;
    Am J Hematol; 2024 Jan; 99(1):79-87. PubMed ID: 37929318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
    Kuter DJ; Rogers KA; Boxer MA; Choi M; Agajanian R; Arnold DM; Broome CM; Field JJ; Murakhovskaya I; Numerof R; Tong S
    Am J Hematol; 2022 Jun; 97(6):691-699. PubMed ID: 35179251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
    Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
    Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
    Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
    Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y;
    Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
    J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia.
    Piatek CI; Bocian H; Algaze S; Weitz IC; O'Connell C; Liebman HA
    Acta Haematol; 2020; 143(3):244-249. PubMed ID: 31665725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
    Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
    J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fostamatinib for the treatment of immune thrombocytopenia in adults.
    Moore DC; Gebru T; Muslimani A
    Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fostamatinib: First Global Approval.
    Markham A
    Drugs; 2018 Jun; 78(9):959-963. PubMed ID: 29869203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial.
    Strich JR; Tian X; Samour M; King CS; Shlobin O; Reger R; Cohen J; Ahmad K; Brown AW; Khangoora V; Aryal S; Migdady Y; Kyte JJ; Joo J; Hays R; Collins AC; Battle E; Valdez J; Rivero J; Kim IH; Erb-Alvarez J; Shalhoub R; Chakraborty M; Wong S; Colton B; Ramos-Benitez MJ; Warner S; Chertow DS; Olivier KN; Aue G; Davey RT; Suffredini AF; Childs RW; Nathan SD
    Clin Infect Dis; 2022 Aug; 75(1):e491-e498. PubMed ID: 34467402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study).
    Michel M; Terriou L; Roudot-Thoraval F; Hamidou M; Ebbo M; Le Guenno G; Galicier L; Audia S; Royer B; Morin AS; Marie Michot J; Jaccard A; Frenzel L; Khellaf M; Godeau B
    Am J Hematol; 2017 Jan; 92(1):23-27. PubMed ID: 27696475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
    Bussel JB; Arnold DM; Boxer MA; Cooper N; Mayer J; Zayed H; Tong S; Duliege AM
    Am J Hematol; 2019 May; 94(5):546-553. PubMed ID: 30784097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
    Taylor PC; Genovese MC; Greenwood M; Ho M; Nasonov E; Oemar B; Stoilov R; Vencovsky J; Weinblatt M
    Ann Rheum Dis; 2015 Dec; 74(12):2123-9. PubMed ID: 25074688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
    Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
    Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world clinical outcomes with fostamatinib for the treatment of refractory chronic immune thrombocytopenia: a single-center experience.
    Moore DC; Elmes JB; Arnall JR; Pineda-Roman M
    Blood Coagul Fibrinolysis; 2024 Sep; 35(6):316-320. PubMed ID: 39012641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fostamatinib for the treatment of chronic immune thrombocytopenia.
    Connell NT; Berliner N
    Blood; 2019 May; 133(19):2027-2030. PubMed ID: 30803989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Kunwar S; Devkota AR; Ghimire DK
    Rheumatol Int; 2016 Aug; 36(8):1077-87. PubMed ID: 27113955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
    Kitas GD; Abreu G; Jedrychowicz-Rosiak K; Miller JL; Nakov R; Panfilov S; Vencovsky J; Wang M; Weinblatt ME; White WB
    J Am Soc Hypertens; 2014 Nov; 8(11):780-90. PubMed ID: 25455003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.
    Tanaka Y; Millson D; Iwata S; Nakayamada S
    Rheumatology (Oxford); 2021 Jun; 60(6):2884-2895. PubMed ID: 33254235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.